SMEK2 Activators

SMEK2 Activators, as a chemical class, encompass a range of compounds that can exert influence over the SMEK2 (PPP4R3B) protein either directly or through indirect modulation of associated cellular pathways. Notably, one of the key pathways intertwined with the SMEK2 domain is the AMPK pathway. Metformin, is an exemplar compound in this category. Recognized primarily for its role in diabetes management, metformin activates AMPK, and in doing so, can modulate the activity of proteins downstream, including SMEK2.

Another pathway that SMEK2 can be associated with is the PI3K/AKT/mTOR axis. Within this axis, the compound LY294002 acts as a PI3K inhibitor. By targeting PI3K, LY294002 can alter the function of proteins downstream, potentially influencing SMEK2 activity. Trichostatin A, serves as an HDAC inhibitor and can impact SMEK2 levels by enhancing histone acetylation, thereby affecting gene expression. In the kinase modulation realm, staurosporine stands out as a broad-spectrum kinase inhibitor. This compound can modulate various pathways, which can, in turn, affect SMEK2, especially if its activity is regulated by phosphorylation. Calcium, a pivotal secondary messenger in cells, can also modulate SMEK2 activity or expression. Verapamil acts as a calcium channel blocker and, by modulating calcium dynamics, can influence SMEK2. Lastly, Forskolin, which raises intracellular cAMP levels, can modulate proteins in cAMP-dependent pathways, thereby influencing SMEK2 activity or expression.